Roche to Speed Up Obesity Market Entry to Catch Up With Rivals, FT Reports

--Roche Holding aims to accelerate its anti-obesity drugs to compete with rivals Eli Lilly and Novo Nordisk after positive results of its obesity pill candidate in an early-stage clinical trial, its Chief Executive Thomas Schinecker told the Financial Times.

--The Swiss pharma company executive said its weight-loss drugs could enter the market earlier than expected, potentially by 2028, the FT reports.

--Schinecker said its $3-billion-plus purchase of Carmot Therapeutics could lead to around seven weight-loss treatments, according to the FT.

Full story: https://on.ft.com/3SpRwDr

Write to Helena Smolak at [e-mail]

(END) Dow Jones Newswires

07-29-24 0206ET